Shareholders Approve New Equity Incentive Plan Authorizing 3.5M Shares

summarizeSummary

Fulgent Genetics shareholders approved the 2026 Equity Incentive Plan, authorizing the issuance of up to 3.5 million new shares for employee and director compensation, representing significant potential dilution.

check_boxKey Events

• Equity Incentive Plan Approved

  Shareholders approved the 2026 Equity Incentive Plan, replacing the prior 2016 plan. This approval was previously proposed in the March 31, 2026 proxy statement.

• Significant Share Authorization

  The new plan authorizes the issuance of 2,000,000 new shares, plus up to 1,500,000 additional shares from forfeited awards under the prior plan, totaling 3,500,000 shares. This represents approximately 11.77% potential dilution based on current outstanding shares.

• Routine Annual Meeting Results

  Shareholders also re-elected all director nominees, ratified Deloitte & Touche LLP as the independent auditor, and approved executive compensation on an advisory basis.

auto_awesomeAnalysis

Fulgent Genetics shareholders have approved a new equity incentive plan, authorizing the issuance of up to 3.5 million new shares for employee and director compensation. This authorization, while a standard practice for talent retention, represents significant potential dilution for existing shareholders, equivalent to approximately 11.77% of current outstanding shares. This follows the company's recent negative financial outlook and materially impacts its capital structure.